Skip to Content

Richard E. Davis, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1984 Medical University of South Carolina, Charleston, SC, MD, Medicine
1979 Clemson University, Clemson, SC, BS, Chemistry

Postgraduate Training

1989-1990 Research Fellowship, Immunodiagnosis, Stanford University, Stanford, CA, Roger Warnke, M.D.


Academic Appointments

Assistant Professor, Department of Pathology, Division of Pathology/Lab Medicine, Stanford University, Stanford, CA, 1990-1998

Other Appointments/Responsibilities

Staff Scientist, National Cancer Institute, Bethesda, MD, 2008-2009
Senior Research Fellow, National Cancer Institute, Bethesda, MD, 2003-2008
Biotechnology Fellow, National Cancer Instittue, Bethesda, MD, 1998-2003

Honors and Awards

1996 Excellence in Teaching-Citation by medical students, Stanford University
1979 Chemistry Department Faculty Award, Clemson University
1979 Undergraduate Analytical Chemistry Award, Clemson University
1978 FDA Merit Award, FDA-Federal Government

Selected Publications

Peer-Reviewed Original Research Articles

1. Voo KS, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, Lee ST, Bover L, Lin HY, Baladandayuthapani V, Delgado D, Luong A, Davis RE, Kwak LW, Liu YJ, Neelapu SS. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer 135(12):2834-46, 12/2014. e-Pub 5/2014. PMID: 24771328.
2. Lu Y, Zhang M, Wang S, Hong B, Wang Z, Li H, Zheng Y, Yang J, Davis RE, Qian J, Hou J, Yi Q. p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat Commun 5:4229, 2014. e-Pub 6/2014. PMID: 24957461.
3. O'Connor C, Sheppard S, Hartline C, Huls H, Johnson M, Palla S, Maiti S, Ma W, Davis RE, Craig S, Champlin R, Wilson H, Cooper L. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma. Scientific Reports 2:249-260, 2012. PMID: 22355761.
4. Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 117(2396):404, 2011. PMID: 21163924.
5. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang ML, Shah JJ, Orlowski RZ. Evidence of a role for activation of Wnt/{beta}-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 286(11009):20, 2011. PMID: 21189262.
6. Davis RE, NgoVN*, Lenz G*, Tolar P, Young R, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang J, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B cell receptor signaling in diffuse large B cell lymphoma. Nature 463:88-92, 2010. PMID: 20805315.
7. Rui L, Emre NCT, Kruhlak MJ, Chung H-J, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao Ho, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM. Cooperative Epigenetic Modulation by Cancer Amplicon Genes. Cancer Cell 18:590-605, 2010. PMID: 21156283.
8. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of Long-Term Storage in Trizol on Microarray-Based Gene Expression Profiling. Cancer Epidemiol Biomarkers Prev(19):2445-52, 2010. PMID: 20805315.
9. Coffey GP, Rajapaksa R, Liu R, Sharpe O, Kuo CC, Krauss SW, Sagi Y, Davis RE, Staudt LM, Sharman JP, Robinson WH, Levy S. Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. J Cell Sci 122(Pt 17):3137-44, 9/2009. e-Pub 8/2009. PMCID: PMC2729262.
10. Davis RE, Staudt LM. Molecular diagnosis of lymphoid malignancies by gene expression profiling. Curr Opin Hematol 9(4):333-8, 7/2002. PMID: 12042708.

Invited Articles

1. Davis RE, Westin JR. Vive la résistance: stem cells in mantle cell lymphoma. Leuk Lymphoma 52:944-5, 2011. PMID: 21463111.

Grant & Contract Support

Title: Predictors Of Clinical Outcome After Therapeutic Vaccination In Follicular Lymphoma
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 3/1/2011 - 2/28/2015
Title: Role of monocytes in immunopathology in human follicular lymphoma
Funding Source: Leukemia and Lymphoma Society
Role: Co-Principal Investigator
Duration: 10/1/2010 - 9/30/2013
Title: Quantitative High-Throughput Screening with a Dual-Luciferase Cell-Based Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2010 - 8/31/2012
Title: M. D. Anderson Cancer Center SPORE in Multiple Myeloma
Funding Source: NIH/NCI
Role: Co-Core Director
Principal Investigator: Orlowski
Duration: 7/2010 - 6/2015
Title: Self-Antigen Dependence of Chronic Active B-Cell Receptor Signaling in the Activated B-Cell Type of Diffuse Large B-Cell Lymphoma
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 3/2010 - 3/2014

Last updated: 4/13/2015